BIO 2 BUSINESS

EVENT MANAGEMENT

BIOTECH OUTSOURCING STRATEGIES 2018

Speaker Programme and Event Content 2018

BASEL2018

19th & 20th June,
Congress Centre Basel, Switzerland.

Discovery & CMC Outsourcing for Small Molecules & Biopharmaceuticals

OUTSOURCING PARTNERING EVENTS FOR THE PHARMACEUTICAL R&D OUTSOURCING COMMUNITY

Launched in 2006, Biotech Outsourcing Strategies Events are niche, outsourcing focused, partnering events for the biotech, pharma and contract services community. The event formula consists of:

- Presentations: From thought leaders in the industry
- 1 to 1 Partnering: Delivered by BOS Events Partnering Software
- Exhibition: Meet leading international CROs and CMOs active in discovery and development stage CMC outsourcing (for both small molecules and biologics)
- Informal Networking: Open and friendly, the BOS ethos encourages networking

In a new and exciting development, BOS 2018 will comprise the existing CMC focused event but in addition, will add a new discovery outsourcing component, creating an enlarged 2 day conference in Basel, Switzerland.

The new format will allow discovery and development teams the opportunity to come together to share experience and knowledge from discovery into development. For our CRO and CMO partners the addition of the discovery component to our existing CMC focused event will present an opportunity to engage with innovator companies at an earlier stage in the R&D continuum.

PRINCIPAL PROGRAMME BLOCKS

OUTSOURCING BUSINESS PROCESS & STRATEGY	TECHNICAL OPERATIONS OUTSOURCING	OUTSOURCING CASE STUDIES	BOS OUTSOURCING SHOWCASE POSTER PRESENTATIONS

WHO SHOULD ATTEND BOS 2018, BASEL

DISCOVERY R&D PROFESSIONALS THOSE INVOLVED IN THE FOLLOWING FUNCTIONS:	CMC R&D PROFESSIONALS THOSE INVOLVED IN THE FOLLOWING FUNCTIONS:
Biotech & Pharma: Target site identification & validation, discovery biology, discovery chemistry, pharmacology, DMPK, lead validation, lead optimisation, in vitro ADME,	**Biotech & Phrma:** PR&D, scale up, drug substance manufacturing, analytical method development, drug product manufacturing, pre-formulation, formulation, outsourcing project managers, external manufacturing, programme managers, contracts managers, CMC procurement
From CROs and CMO: Business development, sales, marketing and corporate management functions	**From CROs and CMO:** Business development, sales, marketing and corporate management functions

All the above to be explored in the context of outsourcing R&D and contract giver/contract acceptor collaboration

FEATURED SPEAKERS

Discovery Outsourcing Speakers

Dr Simon Cruwys
Head of Innovative Medicines Unit, Grunenthal

Simon Cruwys Ph.D is head of the Innovative Medicines Unit (IMU) with Grunenthal R&D. Based in Aachen, Germany but with recently opened Innovation Hubs in Leiden and Boston, the IMU is responsible for search and development activities in pain, new technologies and niche diseases, including fibrosis. The IMU fosters a collaborative, cluster-based, approach to building disease knowledge and improve probability of success via a network of external providers.

He was previously a Team Leader in Bioscience at AstraZeneca R&D Charnwood. His team provided in vitro and in vivo pre-clinical support for a number of projects within the Respiratory and Inflammation area. As a Project Leader, he co-ordinated the progression of candidate drugs from early Discovery through to early stage Development (First Time in Man).

Dr Brice Campo,
Director Drug Discovery, Medicines for Malaria Ventures

Medicines for Malaria Venture (MMV). He leads drug discovery activities in the context of individual projects and pharmacology platforms. As Director Drug Discovery, Brice provides scientific advices and leadership to portfolio of drug discovery activities projects and pharmacology platforms. He works with partners from both academia and industry in order to deliver pertinent and optimal biological test cascades as well as safe and efficacious pre-clinical candidate which will be part of the next generation of anti-malarials. Brice has a particular interest in molecules and biological assays that tackle the liver stage of the parasite and more precisely the hypnozoites reservoir in order to find the new drugs that will help eradicate Malaria. He joined MMV in November 2011, bringing with him more than 14 years of experience in drug discovery, gained primarily with the Genomic Institute of the Novartis Foundation (GNF) and Addex Pharmaceuticals S.A. He has broad experience in molecular pharmacology and drug discovery in several disease areas such as Neuroscience, Metabolic Disease and Inflammation, and has successfully led and contributed to teams at all stages of drug discovery. Brice holds a PhD in Neuroscience and Immunology from the University of Sheffield (UK) and has published a significant number of scientific papers and patent applications.

"BOS CMC has become the most important partnering event in my annual calendar – a great opportunity to catch up with existing collaborators and to forge new business relationships.

Dr Andy Baxter, Director & Discovery and Development Consultant ProPharma Partners Ltd

2017 was my first attendance at BOS and I enjoyed it very much. This seminar was a great time to meet with CMOs in a quiet and relaxed atmosphere. It's been a great opportunity to hear from other's experience and challenges. The human size of BOS allowed an interesting networking and fruitful discussions with our partners. I'm sure to be part of the 2018 session. Many thanks for the good organization.

Carole Mainguet / CMO site manager / PT Development, External Manufacturing F.Hoffmann-La Roche Ltd

BOS cmc is a relevant event to meet customers. The event, well organized, has a good mixture of presentations and partnering opportunities."

Joost Cornelissen, Business Development Manager, BioConnection B.V.

BOS cmc was a very interesting conference with a high number of interesting speeches in

both small and largemolecule space. The think I like the most is the nice combination between

each speech, the one-to-one meetings and the possibility to speak to companies at each stand

without having an excess number of participants.

Michele Gandellini | Account Manager, EIA | Transformational Health | Frost & Sullivan

Biotech Outsourcing Strategies CMC is a very well organised and highly focused event, bringing together drug developers with relevant service providers. The partnering format is ideal as it gives plenty of opportunities to meet and discuss collaborations with new and existing contacts, while still leaving ample time for more informal networking and presentations. This has been a very successful event for us!

Dr Nathalie Huther, Business Development Manager Europe, ACRINOVA

The Bio 2 Business conference has been growing from strength to strength year on year. The presentation session are very educational and very well perceived by the Pharma, Biotec and services companies. There is also a great opportunity to network. Overall this conference is an unique opportunity to collaborate we all parties present.

Michael Kruidenier , Head of Business Development, Quay Pharma,

CMC Outsourcing Speakers

Dr Andrea Calene
Senior Manager, External Manufacturing, Biogen International GmbH

Developing a supplier governance model as part of an integrated supplier relationship strategy

Employed as Senior Manager External Manufacturing at Biogen International, Andrea is supplier relationship manager for the outsourced manufacture of injectable products (Biologicals and Oligonucleotides).

Over the past 15 years Andrea worked in multiple QA and External Manufacturing roles for CSL Behring, Bayer Healthcare and Biogen, managing a relevant number of manufacturing sites and a product portfolio including plasma derivatives, biologicals, as well as non-sterile pharmaceuticals distributed globally.

Starting his career in Corporate Quality Management within a Japanese automotive company (Bridgestone), Andrea developed his professional identity in an environment where outsourcing is key to product compliance as well as to the performance of the supply process.

Andrea holds a M.Sc. in Organic Chemistry from University La Sapienza in Rome, after graduation he completed a Master in Intellectual Property at the Italian Patent and Trade Mark Office. Andrea speaks Italian, English, French, Spanish and German.

Born 1972 in Rome (Italy) Andrea lives in Switzerland with his family since 2005. Andrea is Italian and Swiss national.

Dr Ulrich Ruemenapp
Head of Launch Preparation and Coordination, Bayer.

Dr. Rümenapp is based in Wuppertal, Germany and working within the Biological Development organization of Bayer AG, where he is responsible for the transfer of Bayer's pipeline candidates (antibodies and antibody-drug-conjugates) to external manufacturing partners and regulatory submission and launch preparations.

Prior to working in Development, Dr. Rümenapp was Head of Biotech Projects in Product Supply Biotech at Bayer, where he was responsible for contract manufacturing partnerships in the field of biotechnological drug substances and drug products and interdisciplinary project management with the goal to ensure market supply.

Before it was acquired by Bayer, Dr. Rümenapp hold a similar position at Schering AG, and before that, he worked in the Production & Logistics department of Schering, where he was responsible for production aspects of in- and out-licensing deals, due diligences, and product acquisitions of small molecule products and biologics.

Dr. Rümenapp studied chemistry and holds a Ph.D. in biosciences. He worked several years in academic research in the field of signal transduction and as an assistant teacher in the field of general pharmacology.

Today, Dr. Rümenapp area of expertise is the set-up and management of external relationships for the development and supply of bio-pharmaceutical products. He has more than 15 years of experience in the bio-pharmaceutical industry.

Dr. Rümenapp will be presenting in the CMC Outsourcing Module – biologics track.

Programme BOS 2018 - Day 1

Time	DISCOVERY OUTSOURCING	CMC OUTSOURCING SMALL MOLECULE	CMC OUTSOURCING BIOLOGICS
08.00 - 09.00		Registration & Partnering	
09.00 – 10.30		Outsourcing Process & Strategy	
09.00	**Building a robust, process driven, discovery outsourcing operation.** Dr Jan Huebner, Alliance Manager Technology, Bayer	**Building and integrating a CDMO sourcing strategy in light of transformational change.** Richard Pompe, Director Global Outsourcing CMC, Ipsen & Nicolas Moire, Global Category Leader CDMO, Ipsen	
09.30	**Implementing an effective Preferred Supplier model to support Discovery Outsourcing – an SME perspective.** Dr Brice Campo, Director Drug Discovery, Medicines for Malaria Venture	**Analyze from a methodological perspective SAP "purchase to pay" cycle in CMC R&D for continuous improvement purposes.** Lidia Cappellina, Head of R&D Outsourcing Management, & Massimo Giossi, In/Outsourcing governance & Neo & Special Care Technical Leadership Head, CHIESI FARMACEUTICI S.p.A	
10.00	**Creating transformative business partnerships in drive Discovery.** Dr Peter Hamley, Global Head, External Innovation Drug Discovery, Sanofi	**Evolving from prescriptive outsourcing to a supplier led outsourcing model.** Catharina Lundberg-Niinistö , Sourcing Manager, Senior Specialist, Formulation Development, Orion Corporation ORION PHARMA	
10.30 - 11.00		Coffee & Partnering	
11.00	**BOS Outsourcing Showcase – Poster Presentations showcasing innovation and excellence in Discovery Outsourcing Services & Technologies**	**BOS Outsourcing Showcase – Poster Presentations showcasing innovation and excellence in Small Molecule CMC Services & Technologies**	**BOS Outsourcing Showcase – Poster Presentations showcasing innovation and excellence in Biologics CMC Services & Technologies**
12.00 - 13.30		Lunch & Partnering	
13.30 – 15.30	**Technical Operations Outsourcing – Target ID & Validation to Hit Identification**	**Technical Operations Outsourcing – Early Phase, Small Molecule**	**Technical Operations Outsourcing – Early Phase, Biologics** Chair: Dr Alain Bernard, Director, Independent Biopharma Advisor
13.30	**Accelerating discovery through integrated discovery.** Dr Ulrich Schopfer, Head, Integrated Target and Lead Discovery, Novartis Pharma AG	**Accelerating early API development & sourcing innovative technologies to drive PR&D.**	**Technology transfers from in-licensed assets and from research to CMC development/outsourced manufacture.** Dr Vincent Turula, Director, External Supply BioTherapeutics, Pfizer
14.00	**Optimising biologics early drug discovery.**	**Solid State development for novel modalities, challenges and external solutions.**	**Developing an effective manufacturing strategy for biosimilars..** Dr Andreas Herrmann, CEO, Valerius Biopharma
14.30	**[2+2]-Photocycloaddition for the Synthesis of Cyclobutanes: Access to novel sp3-rich Building Blocks for Medicinal Chemistry.** Dr Thomas Woltering, Section Head Therapeutic Modalities, Medicinal Chemistry 1, Roche	**RNA therapeutics drug product development and experiences of outsourcing for ultra orphan indications.** Maarten Van Geffen, Senior Director, Clinical Supplies & Logistics, ProQR Therapeutics	**CMO Selection and Management: Creating the fundamentals for successful outsourcing partnerships..** Carole Mainguet,, Senior Site Manager, External Manufacturing, Roche.
15.00	**CRO/CMO Presentation – Technical Capabilities**	**CRO/CMO Presentation – Technical Capabilities**	**CRO/CMO Presentation – Technical Capabilities**
15.15	**CRO/CMO Presentation – Technical Capabilities**	**CRO/CMO Presentation – Technical Capabilities**	**CRO/CMO Presentation – Technical Capabilities**
15.30 - 16.00		Coffee & Partnering	
16.00 – 17.30		Outsourcing Case Studies: Contract Giver and Contract Acceptors Showcase Effective Outsourcing Case Studies	
16.00	**Case study 1: Title TBC** Dr Simon Cruwys, Head of Innovative Medicines Unit, Grunenthal	**Development of a scalable synthesis of a novel CXCR3 antagonist: How a network of CMOs contributed to a positive outcome.** Dr Simone Tortoioli, Senior Chemist, Chemical Development, Idorsia Pharmaceuticals	**Start Up Biotech Case Study.**
16.20	**Use of a collaborative tool to simplify the outsourcing of preclinical safety studies: an insight into the AstraZeneca-Charles River Laboratories strategic relationship.** Frederic Martin, Senior Externalisation Specialist (Drug Safety & Metabolism), AstraZeneca	**Development of IV formulations of poorly soluble drugs.** Dr Yogeshwar Bachhav, Associate Director, Pharmaceutical Development, Aicuris GmbH	**Manufacturability of Viral Therapeutics" an emerging field for CDMO's.** Prof Rolf G Werner, Professorship for Industrial Biotechnology, Eberhard Karls University of Tuebingen, Germany
16.40	**Network-driven Drug Discovery (NDD) and New Chemical Entities: Outsourcing Partnerships Case Study.** Sree Vadlamudi, Programme Manager, e-Therapeutics	**Pre-commercial/Early Commercial & Supply Chain Case Study.**	**Developing a supplier governance model as part of an integrated supplier relationship strategy.** Andrea Calenne, Senior Manager External Manufacturing,Biogen
17.00	**Antibody Assisted Drug Discovery – an industry-academia partnership.** Dr Andy Merritt, Associate Director and Head of Chemistry, LifeArc	**Peptides development and Outsourcing.** Frederik Barfoed Beck, Senior Outsourcing Manager, Zealand Pharma	**Flexible Biologics Outsourcing**
17.30 - 19.30		Drinks Reception	

Programme BOS 2018 - Day 2

Time	DISCOVERY OUTSOURCING	CMC OUTSOURCING SMALL MOLECULE	CMC OUTSOURCING BIOLOGICS
08.00 - 09.00		Refreshments & Partnering	
09.00 – 11.00	**Technical Operations Outsourcing – Lead Generation to Lead Optimization**	**Technical Operations Outsourcing – Late Phase, Small Molecule** Chair: Dr Alexander Bausch, CEO, Strekin AG	**Technical Operations Outsourcing – Late Phase, Biologics**
09.00	**New Synthetic Modalities – How to tackle the increasing complexity of a rapidly changing drug discovery environment.** Dr Werngard Czechtizky, Senior Director, Head Medicinal Chemistry, IMED RIA, AstraZeneca	**Strategies for developing a cost-efficient and sustainable manufacturing processes - how outsourcing stakeholders can optimise collaborative development.** Dr Xiaoyong Fu, SVP, API Development & Commercialization at STA Pharmaceutical & Valdas Jurkauskas, Ph.D., Vice President of CMC at Akebia Therapeutics	**Outsourcing late stage development and bio-manufacturing for fast track projects with accelerated timeline – the challenges and needs. Ensuring your external collaboration is fit for purpose.** Dr Ulrich Rümenapp, Head of Launch Preparation and Coordination, Bayer AG
09.30	**Strategies and new technologies driving biologics lead optimization.**	**Implementing a QbD process to guide late phase outsourcing campaigns.**	**Harnessing the opportunities of continuous manufacturing in late phase development.**
10.00	**Transforming lead optimisation through the automation and miniaturisation of chemistry.**	**Successful transitioning from development to commercial contract manufacturing.** Dr. Niko Klan, Director CMO Operations Marketed Products, Merck	**Preparing for potential commercialisation: Managing Fill & Finish process validation in collaboration with your CMO partner.** Dr Aiala Lorente-Trigos, CMC Manager, Novimmune SA
10.30	**CRO/CMO Presentation – Technical Capabilities**	**CRO/CMO Presentation – Technical Capabilities**	**CRO/CMO Presentation – Technical Capabilities**
10.45	**CRO/CMO Presentation – Technical Capabilities**	**CRO/CMO Presentation – Technical Capabilities**	**CRO/CMO Presentation – Technical Capabilities**
11.00 - 11.30		Refreshments & Partnering	
11.30-12.30	**Open Innovation: Progress to date and value creation in the future (Provisional)**	**Continuous Manufacturing Technologies – Harnessing the opportunities for SMEs and Pharma (Provisional)**	**Flexible, Agile and Affordable Bio manufacturing – is it achievable? (Provisional)**
12.30 - 14.00		Lunch & Partnering	
14.00 – 15.30		Outsourcing Case Studies: Contract Giver and Contract Acceptors Showcase Effective Outsourcing Case Studies	
14.00	**Unlocking drug discovery power through collaborative efforts between academia and CRO : bringing novel Tankyrase inhibitors towards the clinic.** Dr Anita Wegert, Director Medicinal Chemistry, Mercachem & Professor Stefan Kraus, Research Team Leader, University of Oslo Hospital	**Making Magic Bullets; Development and Manufacture of Antibody-Drug Conjugates.** Dr Jeremy Parker, Principal Scientist – New Modalities & Tissue Targeting, Early Chemical Development, AstraZeneca	
14.30	**Case Study 2: Contract Acceptor and Contract Giver**	**Case Study 2: Contract Acceptor and Contract Giver**	
15.00	**Case Study 3: Contract Acceptor and Contract Giver**	**Case Study 3: Contract Acceptor and Contract Giver**	
		Conference Close & Drinks Reception	

Featured Presentation:
Evolving from prescriptive outsourcing to a supplier led outsourcing model

Dr Catharina Lundberg-Niinistö,
Sourcing Manager, Senior Specialist, Formulation Development, Orion Corporation ORION PHARMA

Abstract to be confirmed

Featured Presentation:
Making Magic Bullets; Development and Manufacture of Antibody Drug Conjugates

Dr Jeremy Parker, *Principal Scientist – New Modalities & Tissue Targeting, Early Chemical Development, AstraZeneca*

The preparation of Antibody Drug Conjugates (ADCs) presents significant challenges, requiring the preparation of specific antibodies and cytotoxic small-molecule payloads; conjugation of the two species and finally fill-finish. These projects pose significant development and manufacturing challenges, and typically require close collaboration with a range of CMOs.
This talk presents key learning obtained by AstraZeneca/MedImmune in their ADC program which includes a Biparatopic HER2-Targeting Antibody Drug Conjugate currently in Phase I clinical trials.

Poster Abstracts 2017
– A sample of poster abstracts submitted for BOS cmc 2017.

BOS OUTSOURCING SHOWCASE (POSTERS)

Supporting your search for innovative CMO technologies

Innovation highlights 2017

ARCINOVA

Abstract: Arcinova is a Contract Research and Development Organisation (CRDO), providing the life sciences industry with a comprehensive range of services. At Arcinova, we are focused on Process Research, Development, Scale-Up and small scale manufacturing, including bioanalysis, DMPK, regulatory and consulting services, covering drug candidates in Development and launched to the Market. Recently, a request was submitted to Arcinova which required the manufacture of API in a vial to be used in Phase I single ascending dose (SAD) multiple ascending dose (MAD) Phase I trials. The timeline for completion was extremely tight and required manufacture and shipping of the drug product to be executed in 2 days, decreasing the standard duration by more than 2 weeks.

Description: A customer of Arcinova, in the form of a Japanese Big-Pharma Corporation, requested the manufacture of API in a vial to be used in Phase I single ascending dose (SAD) multiple ascending dose (MAD) Phase I trials. The main issue identified with the customer was in regard to the timelines. A rapid 4 day process was required from dose determination to patient administration. As a result of the clinic's location and the time required to ship the product, Arcinova would have a maximum of 48 hours from dose determination to shipping the product to the clinic.

In order to achieve an accelerated manufacturing programme, standard manufacturing procedures were replaced with project specific procedures (see figure below). The project required Arcinova to be agile in its approach, thus creating an efficient and streamlined project. The project specific procedures were managed through Change Controls which were reviewed and approved by Quality Assurance.

A trial was conducted in order to test the new procedure, including a mock shipment exercise. This allowed Arcinova to demonstrate that the timelines were attainable. The trial also provided an opportunity for the clinic to become familiar with Arcinova documentation.

Through the efficient management of change control and creation of project specific procedures, Arcinova managed to reduce the manufacturing and shipment duration from 2-3 weeks to 48 hours.

Category: Drug Product

Type: Small Molecules

Contact: Nathalie Huther (nathalie.huther@arcinova.uk)

Accelerated manufacturing/shipping program at ARCINOVA

ACTIVITY	DURATION
Preparation of a Manufacturing Order by ARCINOVA for client approval *Creation of template Manufacturing Order for client to prepare and provide without delay*	1 day *½ hour*
Preparation and approval of manufacturing documentation (BMI) *Use of Master BMI, pre-approved, for inclusion of batch variables just prior to manufature*	2-3 days *1 hour*
Dispensing of materials and components and component preparation (washing) *Dispensing of materials and components and preparation, for all batches ahead of manufacture to allow immediate availability for manufacture*	1 ½ days *½ hour*
Manufacture *Manufacture*	1 day *1 day*
Documentation review and approval *Documentation review and approval - coordination of all personnel involved*	2-3 days *2 hours*
QC analysis and QA release of product *QC analysis and QA release of product - coordination of all personnel involved*	1-2 days *2 hours*
Dispensing of product and shipping *Not introducing product into GMP stock thereby avoiding dispensing operation*	1 day *2 hours*
TOTAL Standard timelines *TOTAL ARCINOVA Accelerated timelines*	2-3 days *48 hours*

ASYMCHEM

Abstract: Asymchem successfully implemented an industrial scale continuous Ozonolysis process to manufacture 4-Acetoxy-2-Azetidinone (4AA). The adopted system is capable of processing 120kg of starting material (SM) per day to produce multi-ton quantities of product per year. The continuous process provides several advantages (greener, safer, higher throughput and less space required at the manufacturing site) over the batch process, making it very attractive for manufacturing. This poster describes the Ozonolysis process and the different advantages it has to speed up and secure material delivery.



Figure 1: 4-Acetoxy-2-A

Figure 2: Continuous Ozonolysis Process

Description: Continuous Manufacturing (CM) has been successfully implemented at Asymchem for the past 4 years to produce active pharmaceutical ingredients (API) or their intermediates at industrial scale. A continuous Ozonolysis process is currently used to produce 4-Acetoxy-2-Azetidinone (4AA), a heterocyclic synthon for anti-inflammatory and antibiotic agents; see Figure 1.

The system consists of a customized countercurrent temperature controlled packed column where Ozone (O3) bubbles from the bottom and Substrate flows from the top (see Figure 2). The product is collected from the bottom of the column and any reacted/unreacted gas leaves on the top side.

The column has the capacity to process 120kg of starting material (SM) per day or generate 20 metric tons (MT) of product per year. Asymchem decided to run this process in continuous mode rather than batch due to the different advantages it poses: greener, safer, higher material throughput per unit volume and occupies less space.

- Green Process: Less frequent startups and shutdowns allow a reduction in the solvent/gas usage and subsequent generation of waste. Also, the tail or excess gas (O3/O2) is collected and reused for oxidation of organics at the site's waste water treatment plant.

- Safer: The residual volume in the packed column, at any point in time, is approximately 16 liters; this is significantly less residual volume when compared to its equivalent in batch (i.e. 1,000 liters). As such, less material (SM or product) is at risk when running the process in flow mode.

- Higher conversion and throughput per unit volume
- The use of special packing increases the surface area and mass transfer between the gas & liquid media, this enhances the conversion of SM in less time. Due to its continuous nature (operating at steady state), the Ozonolysis system can process 63% more material per unit volume than the batch process.

- Less space at plant site: The Ozonolysis column occupies approximately 8 times less plant space than the equivalent batch reactor.

The manufacturing of 4AA, using a continuous platform, provided significant benefits compared to its homologous in batch mode. Producing more material in less amount of time and using less space made this process attractive to do it in flow mode. Asymchem constantly evaluates and adopts CM opportunities to make more efficient processes

Category: Drug Substance

Type: Small Molecules

Contact: Jordi Robinson (JordiRobinson@asymchem.com)

> The conference was an excellent opportunity to meet a variety of CMOs in the DS/DP field and have sufficient time for discussion. The timetables available prior to the meeting were a very helpful tool in setting the meetings. The talks I attended during the sessions were informative and the diversity of attendees and presenters represented a wide cross section of the industry.
>
> Mirjam Sax, PhD, Principal Site Manager, External Development Collaborations, PTDMX Small Molecules, F. Hoffmann-La Roche Ltd

> BOS CMC 2017 was a very informative congress which allows one 2 one meeting with CMOs and other collaborators, which is quite unique compared to other congresses. The topics covered in this congress were also very interesting and provided insight to all the relevant challenges regularly faced by biotech companies during outsourcing activities. Overall the event was organized meticulously by the organizers.
>
> Yogeshwar Bachhav, Associate Director Pharmaceutical Development, Aicuris GmbH

> I would like to thank you again for the opportunity of joining this exciting event. BOS cmc is the place where Analytical CROs meet CMOs together with outsourcing professionals! Because of its relatively small size, you can have the opportunity of knowing more providers experiencing their approach on the main CRO/CMO activities.
>
> Gabriele Sassi, Non Clinical Outsourcing Manager, R&D Outsourcing Management, CHIESI FARMACEUTICI S.p.A.

> Very interesting event for specific networking and selective information sourcing on CROs and CMOs. Very informative talks from experts with many relevant case studies Good size and venue.
>
> Mario Amacker, PhD, Head of Quality & Manufacturing, Mymetics BV

Biotech Outsourcing Strategies: Facilitating partnering between Contract Giver and Contact Acceptor



BOS Outsourcing Partnering Dynamic

BOS Event Components Delivering Partnering & Matchmaking

BOS PARTNERING SOFTWARE

All attendees will have access to the BOS Partnering Software. This platform allows participants to contact one another prior to the event to arrange 1-to-1 meetings. Confirmed meeting will then be scheduled into your agenda during the event. Further details describing this process are provided below:

Step 1: 4 weeks prior to the event, Biotech & Pharma participants (Contract Giver) invited to access the Partnering software and outline outsourcing requirements e.g. Looking for aseptic fill and finish capabilities.

Step 2: 3 weeks prior to the event, CRO and CMO participants receive credentials to access the partnering and are invited to outline outsourcing capabilities and 1-to-1 meeting objectives

Step 3: 3 weeks – 1 day prior to event. Partnering software fully operational. Delegates can use the software to send meeting requests, based on a specific timeslot, to a fellow delegate who can then accept or decline the meeting request.

Step 4: Accepted meeting requests will be scheduled in your agenda at the requested timeslot. You will be able to view your finalised 1-to-1 meeting agenda electronically.

Step 5: Go to the allocated partnering table (as shown on your agenda) or exhibitor stand at the specified time to conduct your 1-to-1 meeting



CRO & CMO EXHIBITION

BOS Events are built around the exhibition space. Our venue has been carefully selected to offer an "open plan" space, which allows exhibiting CROs and CMOs the opportunity to present the full breadth of their capabilities to the attending biotech and pharma community. See details of the floor plan below.

BOS OUTSOURCING SHOWCASE (POSTERS)

Showcasing break-through technologies and innovations BOS 2018 will highlight the best of innovation in the CRO/CMO sector and in turn allow you to keep fully abreast of technology developments shaping the future of discovery and CMC outsourcing.

Posters on Display at BOS cmc 2017, Basel.

Go to http://www.bio2bevents.com/registration to complete your registration enquiry online

Book Now By:
Registering Online: http://www.bio2bevents.com/registration
By Phone: +44 (0)207 691 3568 By Email: info@bio2business.com

Prices do not include VAT. Please see 2017 Media Pack for full details (available on request from Bio2Business)

Biotech & Pharma Package

£545 + VAT
Available to biotech and pharma delegates (non service providers only)

Sponsor Package	Features	Price 2 Day Event (Basel) GBP
Key Sponsor	Ask Bio2Business for details	
Gold Sponsor	• 15 minute presentation opportunity to BOS audience as part of the BOS 2018 programme of speakers. • 3m wide x 2m high exhibition stand space. • Permanent logo (max 130 pixels in width) on BOS homepage with hotlink to sponsor website • Speaker biography and full page company profile in delegate pack with no images, logos, or formatting design changes • Full utilisation of BOS partnering software • Access to "Meet at Stand Function" within BOS Partnering Software 3 weeks prior to event • X5 delegate attendance • On-site poster included as BOS Outsourcing Showcase Package (presentation in BOS Outsourcing Showcase Package not included - see separate details • Online profile published on BOS 2018 website to include 200words, contact name, tel no, address	£9,000 (X5 delegates)
Exhibition Sponsor	• Exhibition/stand space (3m wide x 2m high) • Rotating logo (max 130 pixels in width) on BOS homepage with hotlink to sponsor website • Half page company profile in delegate pack with no images, logos, or formatting design chagnes • Full utilisation of BOS partnering software • Access to "Meet at Stand Function" within BOS Partnering Software 3 weeks prior to event • X4 Delegate attendance • Online profile published on BOS 2018 website to include 200 words, contact name, tel no, address	£6,650 (X4 delegates)
Exhibition Banner Stand	• 1 Banner Stand (max 1.2m width) only (no furniture, no electricity) • Rotating logo (max 130 pixels in width) on BOS homepage with hotlink to sponsor website • Logo (max 130 pixels in width) • on BOS 2018 home page (1 slot shared with other exhibition sponsors – random selection). • Half-page profile in delegate pack with no images, logos, or formatting design changes • Full utilisation of BOS partnering software 3 weeks prior to event • X3 delegate passes • Online profile published on BOS 2018 website to include 200 words, contact name, tel no, address	£5,500 (X3 delegates)
Silver Sponsor	• Logo (max 130 pixels in width) on BOS home page (1 slot shared with other • silver sponsors – random selection). Half-page profile in delegate pack with no images, logo or formatting design changes • Full utilisation of BOS partnering software 3 weeks prior to event • x1 x2 or x3 delegate passes • Online profile published on BOS 2018 website to include 200 words, contact name, tel no, address • Half-page profile in delegate pack with no images, logos, or formatting design changes	£3,350 (x1 delegate) £4,250 (X2 delegates) £5,150 (X3 delegates)
CRO Sponsor	• Full access to the BOS event for 1 delegate • Full utilisation of partnering software 2 weeks prior to event	£2,850
Extra delegates	*VAT to be added where appropriate*	£900 (x1 delegate)

Key CRO Sponsors

Gold Sponsors

anacura
Patheon part of Thermo Fisher Scientific
amri Complex Science. Expert Solutions.

Exhibition Sponsors

ALTHEA
Quality Assistance Contract Research Organisation
pci PHARMA SERVICES
CARBOGEN AMCIS A Dahman Group Company
NAVIN FLUORINE INTERNATIONAL LIMITED
ALMAC
ASYMCHEM 凯莱英医药集团 Asymchem Labs.
SYNCOM Designing Chemistry

Silver Sponsors

Piramal Pharma Solutions
STA WuXi AppTec

Host Sponsors

Events Partners

BIOTECH GATE GLOBAL DATABASE